ERBB2 and breast carcinoma: The clinical advantage of increased numbers of TILs provides an impetus for future research to integrate novel immunotherapy with conventional therapy, and additional studies should focus on immune regulation mechanism in different breast cancer subtypes and understand anticancer immune response in HER2-positive breast cancer and TNBC.